https://www.live-feeds.com/feed/eli-lilly-s-foundayo-obesity-pill-eases-sleep-apnea-in-late-stage-trial-paving-way-for-approvalContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/eli-lilly-s-foundayo-obesity-pill-eases-sleep-apnea-in-late-stage-trial-paving-way-for-approvalhttps://www.live-feeds.com/feed/eli-lilly-s-foundayo-obesity-pill-eases-sleep-apnea-in-late-stage-trial-paving-way-for-approval#u198613Fri, 13 Nov 2026 10:55:11 +0000Eli Lilly reported that its daily oral weight-loss drug Foundayo met its main goal in a late-stage clinical trial involving adults with obesity and obstructive sleep apnea. The Phase 3 ATTAIN-OSA study demonstrated that the daily GLP-1 pill significantly reduced obstructive sleep apnea severity, pointing to health benefits beyond weight loss. The pharmaceutical company intends to submit the data for FDA review and pursue a wider global rollout for sleep apnea treatment in this population. Analysts suggest the positive results could open a multi-billion-dollar market for the oral treatment.Why